Teva Pharmaceuticals, USA, Inc. v. Leavitt’s Empirical Analysis
548 F.3d 103 · 2008
Citation profile
7 federal appellate · 4 district ·
How this case has been cited
Cited by 21 later decisions — most recently December 2024
7 federal appellate · 4 district ·
Later decisions citing this case, by decade. The current decade is in progress, and our corpus holds fewer opinions from the most recent years, so the latest bars are undercounted — not a real decline.
Relationships
Applies 21 U.S.C. § 355 (§ 505 of the All Kids Act) · 35 U.S.C. § 271
Relies on Chevron U. S. A. Inc. v. Natural Resources Defense Council, Inc. · Yee v. City of Escondido · Mova Pharmaceutical Corp. v. Shalala · American Bioscience, Inc. v. Thompson · Engine Manufacturers Ass'n v. U.S. Environmental Protection Agency
Most-quoted passages
The sentences later courts lift from this opinion, ranked by how many decisions quote each — the parts of the opinion doing the work. These counts are smaller than the citation total above because most of the 21 citing decisions cite the case generally; a passage count includes only decisions quoting that exact language verbatim.
“(I) that such patent information has not been filed [a "Paragraph I certification"], (II) that such patent has expired [a "Paragraph II certification"], (III) of the date on which such patent will expire [a "Paragraph III certification"], or (IV) that such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted [a "Paragraph IV certification"].”
2 later decisions quote this exact passage · from the majority“piggyback[ ] on the original manufacturer's evidence of safety and efficacy,”
2 later decisions quote this exact passage · from the majority“compensate [generic] manufacturers for research and development costs as well as the risk of litigation from patent holders,”
1 later decision quote this exact passage · from the majority
How this case has been treated — in progress
Whether each later court followed, distinguished, criticized, or overruled this decision. The treatment classification (task #35) runs highest-cited cases first and lights up here as it reaches this one.